|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC Network study
Karim Labreche
,
Mailys Daniau
,
Amit Sud
,
Philip J Law
,
Louis Royer-Perron
et al.
Journal articles
hal-02328989v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial
Anne Bouvier
,
Jean-Francois Hamel
,
Jacques Delaunay
,
Eric Delabesse
,
Pierre-Yves Dumas
et al.
Journal articles
hal-03604930v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Prospective, Multicentric Phase II Randomized Trial Comparing the Efficacy of Methotrexate or Cyclophosphamide in Large Granular Lymphocytic Leukemia: A French National Study. Report on the Interim Analysis
T. Lamy
,
C. Pastoret
,
R. Houot
,
Loic Ysebaert
,
M. Hunault
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. 134 (Suppl 1), pp.1545, 2019, Blood
Conference poster
hal-02427556v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Management and outcome of primary CNS lymphoma in the modern era
Caroline Houillier
,
Carole Soussain
,
Hervé Ghesquières
,
Pierre Soubeyran
,
Olivier Chinot
et al.
Journal articles
hal-02872770v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
R-CHOP 14 with or without radiotherapy in non-bulky limited-stage diffuse large B-cell lymphoma (DLBCL)
Thierry Lamy
,
Gandhi Damaj
,
Pierre Soubeyran
,
Emmanuel Gyan
,
Guillaume Cartron
et al.
Journal articles
hal-01635792v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|